Periodontitis-associated metabolite isoleucine impairs intestinal barrier function and exacerbates intestinal inflammatory response by NF-κB signaling

Xiaoxue Wang, Yilin Luo, Jie Ren, Huifang Xie, Marco Aoqi Rausch, Xiaohui Rausch‐Fan, Fei Hu, Xueyang ZhangFrontiers in Cellular and Infection Microbiology 2025 · DOI

TL;DR

This study reveals how periodontitis, a common oral infection, can worsen inflammatory bowel disease (IBD) like colitis. The culprit is a metabolite called isoleucine (Ile), produced by oral bacteria, which damages the gut lining and amplifies inflammation by activating the NF-κB signaling pathway. This work highlights a crucial link between oral health and gut health, suggesting potential therapeutic targets.

What Problem Does This Paper Address?

Periodontitis, a chronic inflammatory disease of the gums, has been increasingly linked to systemic health issues, including inflammatory bowel diseases (IBD) like ulcerative colitis (UC). While epidemiological studies and animal models show a correlation, the precise mechanisms by which periodontitis exacerbates colitis remain unclear. Specifically, researchers wanted to understand if specific molecules produced by the oral microbiota in periodontitis could directly impact the intestinal barrier and inflammatory responses in the gut. This paper focuses on isoleucine (Ile), a metabolite found to be elevated in periodontitis patients, and investigates its role in this oral-gut axis.

Methods

The researchers employed a multi-pronged approach using mouse models and cell cultures:

  • Animal Models:
    • Experimental Periodontitis and Colitis Model: C57BL/6J mice were subjected to a ligature-induced periodontitis model and a dextran sulfate sodium (DSS)-induced colitis model, both individually and in combination. This allowed them to observe the effects of periodontitis alone, colitis alone, and the combined condition.
  • Ile Gavage Model: Mice with DSS-induced colitis were also administered Ile orally to directly assess its impact on colitis.
  • IKK-16 Treatment: To investigate the role of the NF-κB pathway, a specific inhibitor (IKK-16) was administered to mice in the combined periodontitis and colitis model.
  • Histology and Immunostaining: Tissues (gingiva and colon) were analyzed using Hematoxylin and Eosin (HE) staining to assess structural damage and inflammation. Immunohistochemistry was used to examine the expression of tight junction proteins (ZO-1 and occludin), crucial for maintaining the intestinal barrier.
  • Intestinal Permeability Assay: The integrity of the intestinal barrier was measured using FITC-dextran, a fluorescent marker that leaks into the bloodstream when the barrier is compromised.
  • Molecular Analysis:
    • Quantitative Real-Time PCR (qRT-PCR): mRNA levels of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) were quantified.
  • Western Blot: Protein levels of key components of the NF-κB signaling pathway (p-IκBα, IκBα, p-P65, P65) were assessed.
  • Cell Culture:
    • IEC-6 Cells: Intestinal epithelial cells (IEC-6) were treated with LPS (to mimic inflammation) and/or Ile to study the direct effects on barrier function and NF-κB activation.
  • Intestinal Organoids: Organoids derived from intestinal crypts were used to assess the impact of Ile on epithelial damage and inflammatory responses under TNF-α stimulation.

The study utilized standard techniques for animal modeling, histology, and molecular biology, with a focus on dissecting the NF-κB signaling pathway and its interaction with Ile.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • The Oral-Gut Connection is Mechanistic: This study moves beyond correlation to demonstrate a direct mechanistic link between periodontitis and colitis, mediated by a specific bacterial metabolite.
  • Isoleucine as a Key Culprit: Ile, a common amino acid, emerges as a significant player. Its elevated levels in periodontitis are shown to directly impair the intestinal barrier and amplify inflammation. This suggests that targeting Ile production or metabolism could be a therapeutic strategy.
  • NF-κB: The Central Signaling Hub: The NF-κB pathway is identified as the critical mediator. Ile appears to "turn up the volume" on this pathway, leading to increased production of inflammatory cytokines and breakdown of the gut barrier.
  • Periodontitis Amplifies Existing Inflammation: Ile doesn't necessarily initiate inflammation on its own but significantly potentiates existing inflammatory signals (like LPS or TNF-α), acting as a potent amplifier.
  • Targeting NF-κB Offers Hope: The successful rescue of intestinal barrier function and reduction of inflammation by the NF-κB inhibitor IKK-16 in mouse models strongly supports the central role of this pathway and suggests it as a viable therapeutic target.

Key Results

  • Periodontitis Worsens Colitis: Mice with both periodontitis and DSS-induced colitis showed significantly worse outcomes (higher weight loss, increased disease activity index, shorter colon length, and more severe histological damage) compared to mice with only colitis.
  • Ile Impairs Gut Barrier: Ile administration in colitis models led to increased intestinal permeability and decreased expression of tight junction proteins (ZO-1 and occludin) in the colon.
  • Ile Activates NF-κB: Ile treatment in both in vivo and in vitro models significantly upregulated key components of the NF-κB signaling pathway (e.g., increased p-P65 and p-IκBα).
  • Ile Enhances Cytokine Production: Ile potentiated the expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in intestinal epithelial cells, particularly in the presence of inflammatory stimuli.
  • IKK-16 Rescues Barrier Function: Treatment with the NF-κB inhibitor IKK-16 reversed the Ile-induced impairment of intestinal barrier function and reduced inflammation in colitis models.

Limitations and Future Work

The authors acknowledge several limitations and suggest future research directions:

  • Single-Sex Study: The current study used only female mice. Future work should validate these findings in both sexes to ensure broader applicability.
  • Ile Concentration and Transport: While Ile was shown to be a modulatory amplifier, the exact physiological concentration of Ile entering the gut from periodontitis and its specific transport mechanisms into intestinal epithelial cells remain unclear. Future studies should explore these aspects, potentially using metabolic tracing.
  • Role of ROS: The involvement of reactive oxygen species (ROS) in Ile-induced NF-κB activation was not directly investigated but is a known mechanism for other branched-chain amino acids. This warrants further exploration.
  • NF-κB/MLCK Axis: The paper hypothesizes that Ile might decrease TJ protein expression via the NF-κB/MLCK axis, but this requires direct experimental validation.
  • Th17/IL-17 Axis: The study noted the enrichment of the IL-17 signaling pathway, suggesting it as another potential mechanism by which Ile exacerbates colitis, which needs further investigation.
  • Long-term Toxicity of Inhibitors: While IKK-16 showed promise, its long-term toxicity in humans needs to be evaluated before clinical application.
  • Human Validation: Ultimately, validating these findings in human samples is crucial to confirm the role of Ile and the NF-κB pathway in periodontitis-associated colitis.

The authors emphasize the need for further research into the precise mechanisms and potential therapeutic interventions, including improving oral hygiene, dietary modifications, and targeted NF-κB inhibition.

Summary updated

Abstract

Our study unraveled that periodontitis contributed to intestinal barrier function damage and inflammation of intestinal epithelial cells by potentiating NF-κB signaling in the context of colitis and that this was associated with periodontitis-associated metabolite Ile.
BibTeX
@inproceedings{wang2025periodontitis,
  author = {Xiaoxue Wang and Yilin Luo and Jie Ren and Huifang Xie and Marco Aoqi Rausch and Xiaohui Rausch‐Fan and Fei Hu and Xueyang Zhang},
  title = {{Periodontitis-associated metabolite isoleucine impairs intestinal barrier function and exacerbates intestinal inflammatory response by NF-κB signaling}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  doi = {10.3389/fcimb.2025.1684362},
}
Figure